The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao

• Autori principali: Hui Mo (Autore), Man-Fei Zhou (Autore), Edmundo Patricio Lopes Lao (Autore), Ka-Kei Chan (Autore), On-Na Lai (Autore), Man-In Ho (Autore), Kin-Wa Wong (Autore), Ka-Meng Ho (Autore), Kin-Tim Sio (Autore), Keng-Lam Fong (Autore), Yong-Hua Zhao (Autore), Seng-Ip Cheang (Autore), Iek-Long Lo (Autore)
• Natura: Libro
• Pubblicazione: BMC, 2024-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Background COVID-19 is continuing to ravage globally and has resulted in a huge health and financial burden. Chinese proprietary medicines, such as Lianhua Qingwen (LHQW) and Huoxiang Zhengqi (HXZQ) capsules, have been recommended for non-high-risk patients with COVID-19 in China. Based on...